Procathepsin D in breast cancer: What do we know? Effects of
ribozymes and other inhibitors

J 2002

Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors

VETVIČKA, V., Petr BENEŠ and M. FUSEK

Basic information

Original name

Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors

Name in Czech

Prokatepsin D v rakovině prsu. Co o něm víme? Účinek ribozymů a ostatních inhibitorů.

Authors

VETVIČKA, V. (203 Czech Republic), Petr BENEŠ (203 Czech Republic, guarantor) and M. FUSEK (203 Czech Republic)

Edition

Cancer Gene Therapy, England, Nature Publishing Group, 2002, 0929-1903

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

Genetics and molecular biology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.929

Organization unit

Faculty of Science

Keywords in English

procathepsin D; cathepsin D; breast cancer; receptor

Abstract

ORIG CZ

V originále

Procathepsin D (pCD) is a major secreted glycoprotein in some human breast and other cancer cell lines. Several groups proposed that pCD served as a growth factor for these cell lines. Secreted pCD has been demonstrated in tissue section, tissue culture supernatants, carcinoma cytosols, and nipple aspirates. Moreover, several clinical studies suggested a potential role for this molecule in metastasis because its concentration in primary tumors correlated with an increased incidence of tumor metastases. In this paper, the effects of pCD were evaluated by proliferation in vitro and by mouse studies in vivo. Subsequent flow cytometry experiments showed the specificity of pCD binding to cancer cells. Cell cultivation showed that addition of either pCD or its activation peptide stimulates growth of cancer cells. These effects can be inhibited both in vitro and in vivo by anti-pCD antibodies. In addition, production of pCD can be inhibited by specifically designed ribozymes. This paper is focused on mitogenic effects of pCD, which seem to involve interaction of the activation peptide with as yet unidentified receptor. Different mechanisms by which pCD could promote development and spread of cancer cells are discussed.

In Czech

Prokatepsin D je hlavn9m sekretovaným glykoproteinem některých lidských rakoviných linií, u kterých slouží jako růstový faktor. Některé studie naznačují i jeho možný pro-metastatický potenciál. V této práci byl hodnocen vliv pCD na proliferaci in vitro a in vivo a sledován efekt různých inhibitorů na pCD zprostředkovaný mitogenní efekt.

Citovat

VETVIČKA, V., Petr BENEŠ and M. FUSEK. Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors. Cancer Gene Therapy. England: Nature Publishing Group, 2002, vol. 2002, No 9, p. 854-863. ISSN 0929-1903.

@article{405579,
   author = {Vetvička, V. and Beneš, Petr and Fusek, M.},
   article_location = {England},
   article_number = {9},
   keywords = {procathepsin D; cathepsin D; breast cancer; receptor},
   language = {eng},
   issn = {0929-1903},
   journal = {Cancer Gene Therapy},
   title = {Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors},
   volume = {2002},
   year = {2002}
}

TY  - JOUR
ID  - 405579
AU  - Vetvička, V. - Beneš, Petr - Fusek, M.
PY  - 2002
TI  - Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors
JF  - Cancer Gene Therapy
VL  - 2002
IS  - 9
SP  - 854
EP  - 854
PB  - Nature Publishing Group
SN  - 09291903
KW  - procathepsin D
KW  - cathepsin D
KW  - breast cancer
KW  - receptor
N2  - Procathepsin D (pCD) is a major secreted glycoprotein in some human breast and other cancer cell lines. Several groups proposed that pCD served as a growth factor for these cell lines. Secreted pCD has been demonstrated in tissue section, tissue culture supernatants, carcinoma cytosols, and nipple aspirates. Moreover, several clinical studies suggested a potential role for this molecule in metastasis because its concentration in primary tumors correlated with an increased incidence of tumor metastases. In this paper, the effects of pCD were evaluated by proliferation in vitro and by mouse studies in vivo. Subsequent flow cytometry experiments showed the specificity of pCD binding to cancer cells. Cell cultivation showed that addition of either pCD or its activation peptide stimulates growth of cancer cells. These effects can be inhibited both in vitro and in vivo by anti-pCD antibodies. In addition, production of pCD can be inhibited by specifically designed ribozymes. This paper is focused on mitogenic effects of pCD, which seem to involve interaction of the activation peptide with as yet unidentified receptor. Different mechanisms by which pCD could promote development and spread of cancer cells are discussed.
ER  -

VETVIČKA, V., Petr BENEŠ and M. FUSEK. Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors. \textit{Cancer Gene Therapy}. England: Nature Publishing Group, 2002, vol.~2002, No~9, p.~854-863. ISSN~0929-1903.

Detailed Information on Publication Record